Nevro Corp (NASDAQ:NVRO) CFO Andrew H. Galligan sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $86.90, for a total transaction of $651,750.00. Following the completion of the transaction, the chief financial officer now owns 33,315 shares in the company, valued at approximately $2,895,073.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Nevro Corp (NASDAQ:NVRO) opened at 88.29 on Friday. The firm’s market cap is $2.54 billion. The company has a 50-day moving average of $93.38 and a 200-day moving average of $84.45. Nevro Corp has a 52 week low of $47.07 and a 52 week high of $106.93.

A number of large investors have recently bought and sold shares of the company. M&T Bank Corp boosted its stake in Nevro Corp by 16.2% in the second quarter. M&T Bank Corp now owns 7,359 shares of the company’s stock worth $543,000 after buying an additional 1,025 shares during the last quarter. California Public Employees Retirement System boosted its stake in Nevro Corp by 37.1% in the second quarter. California Public Employees Retirement System now owns 13,300 shares of the company’s stock worth $981,000 after buying an additional 3,600 shares during the last quarter. Emerald Acquisition Ltd. bought a new stake in Nevro Corp during the second quarter worth approximately $6,949,000. Mariner Investment Group LLC bought a new stake in Nevro Corp during the second quarter worth approximately $954,000. Finally, Swiss National Bank boosted its stake in Nevro Corp by 32.2% in the second quarter. Swiss National Bank now owns 33,700 shares of the company’s stock worth $2,486,000 after buying an additional 8,200 shares during the last quarter.

Nevro Corp Company Profile

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.

5 Day Chart for NASDAQ:NVRO

Receive News & Stock Ratings for Nevro Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp and related stocks with our FREE daily email newsletter.